Related Experiment Videos
[Therapy of hormone refractory prostatic carcinoma]
Der Urologe. Ausg. A
|May 1, 1998
Summary
For hormone-resistant prostate cancer, quality of life is key when androgen deprivation fails. Chemotherapy offers transient benefits, but symptom-related pain relief may be equally effective.
Area of Science:
- Oncology
- Urology
Context:
- Hormone-resistant prostate cancer (HRPC) presents unique challenges after initial androgen deprivation therapy (ADT) failure.
- Progressive disease in HRPC necessitates a shift in treatment goals towards palliative care and quality of life (QoL).
Purpose:
- To outline secondary treatment strategies for HRPC focusing on symptom management and QoL improvement.
- To evaluate the role of chemotherapy and surgical interventions in advanced prostate cancer.
Summary:
- Secondary treatment for HRPC is guided by clinical symptoms, prioritizing QoL over survival prolongation.
- While single-agent chemotherapy can provide transient benefits, its superiority over symptom-related pain relief is unproven.
- Surgical options like transurethral resection of the prostate (TURP) and spinal cord decompression are indicated for symptomatic local or systemic progression.
Impact:
- This information aids clinicians in managing HRPC by emphasizing palliative care and symptom control.
- Highlights the importance of individualized treatment decisions based on patient symptoms and QoL in advanced prostate cancer.